The effect of integrated cardiac rehabilitation versus treatment as usual for atrial fibrillation patients treated with ablation: the randomised CopenHeartRFA trial protocol

Signe Stelling Risom,1 Ann-Dorth Olsen Zwisler,1,2 Trine Bernholdt Rasmussen,1,3 Kirstine Lærum Sibilitz,1 Jesper Hastrup Svendsen,1,4 Christian Gluud,5 Jane Lindschou Hansen,5 Per Winkel,5 Lau Caspar Thygesen,2 Merja Perhonen,6 Jim Hansen,3 Sandra B Dunbar,7 Selina Kidkenborg Berg1,3

ABSTRACT

Introduction: Atrial fibrillation affects almost 2% of the population in the Western world. To preserve sinus rhythm, ablation is undertaken in symptomatic patients. Observational studies show that patients with atrial fibrillation often report a low quality of life and are less prone to be physically active due to fear of triggering fibrillation. Small trials indicate that exercise training has a positive effect on exercise capacity and mental health, and both patients with recurrent atrial fibrillation and in sinus rhythm may benefit from rehabilitation in managing life after ablation. No randomised trials have been published on cardiac rehabilitation for atrial fibrillation patients treated with ablation that includes exercise and psychoeducational components.

Aim: To test the effects of an integrated cardiac rehabilitation programme versus treatment as usual for patients with atrial fibrillation treated with ablation.

Methods and analysis design: The trial is a multicentre parallel arm design with 1:1 randomisation to the intervention and control group with blinded outcome assessment. 210 patients treated for atrial fibrillation with radiofrequency ablation will be included. The intervention consists of a rehabilitation programme including four psychoeducative consultations with a specially trained nurse and 12 weeks of individualised exercise training, plus the standard medical follow-up. Patients in the control group will receive the standard medical follow-up. The primary outcome measure is exercise capacity measured by the VO2 peak. The secondary outcome measure is self-rated mental health measured by the Short Form 36 questionnaire. Postintervention, qualitative interviews will be conducted in 10% of the intervention group.

Ethics and dissemination: The protocol is approved by the regional research ethics committee (number H-1-2011-135), the Danish Data Protection Agency (reg. nr. 2007-58-0015) and follows the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and may possibly impact on rehabilitation guidelines.

Trial registration: Clinicaltrials.gov identifier: NCT01523145.
ARTICLE SUMMARY

Strengths and limitations of this study
- The study has been designed to meet the criteria for high quality in non-pharmacological randomised clinical trials with central randomisation, multicentre participation, blinded assessment and analysis.
- We are aware of the day-to-day variation that can appear when carrying out ergospirometry in testing and that the performance can depend on the individual tester. Accordingly, we will interpret the findings conservatively.

INTRODUCTION

Atrial fibrillation (AF) is the most common sustained arrhythmia and affects 2% of the population in the Western world.1–3 Typical symptoms are palpitations, dyspnoea, fatigue, dizziness and syncope. Patients’ symptoms and the length of periods in AF are highly variable both for the individual and between patients.4–6 AF is associated with increased risk of stroke, other thromboembolic events and heart failure.6–8 Hospitalisations due to AF account for one-third of all admissions for cardiac arrhythmias.9 As the prevalence of AF increases with age, the incidence of AF is increasing due to an ageing population.2,9,10 After 40 years of age, the lifetime risk of developing AF is 25%.11 The annual cost of AF is high in comparison with other diseases.12 Therefore, AF has become an economic burden that will continue to increase over the coming decades.13 Thus, AF has now become a health, social and economic challenge in the Western world.14

Primary treatment goals for individuals with AF are re-establishing and maintaining sinus rhythm, decreasing AF symptoms and preventing complications. In accordance with current national and international guidelines, radiofrequency ablation (RFA) is often undertaken in symptomatic patients. RFA is an invasive treatment, intended to cure AF, and has a success rate of 77% versus 52% for antiarrhythmic medication.15 In Denmark, around 600 RFA s are conducted annually at two heart centres.

A cohort study of 655 patients from a randomised trial found that AF symptoms are a negative predictor for patients’ physical capacity,16 and in the presence of AF, patients do fewer physical activities.17 Smaller observational studies and a randomised trial investigating the effect of exercise training on AF patients found increased exercise capacity and a decreased resting heart rate after training.18–20

Previous studies show a significantly impaired quality of life in patients with AF compared with healthy controls measured by the questionnaire Short Form 36 (SF-36). The general health component (±SD) was 54±21 in AF patients compared with 78±17 in healthy controls.21 A qualitative study demonstrated that educational help after AF treatment is lacking, even though symptoms of distress and lack of self-management regarding symptoms like palpitations, dyspnoea and fatigue are common.22 Furthermore, small observational studies indicate a positive effect of exercise training on patients with AF in terms of mental health and physical activity (15% increase of VO2).18,19 However, these findings need confirmation in larger randomised clinical trials.

Secondary prevention initiatives including cardiac rehabilitation are recommended by the European Society of Cardiology (ESC).23 Studies exploring the effects of rehabilitation for patients treated for AF are lacking. As there is no evidence of its efficacy, rehabilitation is not systematically provided in Denmark and most often patients treated for AF with RFA are not offered any rehabilitation at all. The evidence for general cardiac rehabilitation is strong, but it is found that it is poorly implemented and only selected patient groups are offered full comprehensive cardiac rehabilitation programmes, even though ESC recommends such programmes.24 Research has mainly been conducted within patients with coronary heart disease and heart failure, where rehabilitation has been proven to reduce hospital readmissions and mortality in a cost-effective way,25,26 as well as to improve the quality of life.27 More specifically, studies on the effect of exercise training have demonstrated an increase in exercise capacity of up to 38% in patients after valve replacement surgery28 and an increase in peak VO2 of 2.3±2.2 (SD) ml/kg/min in the intervention group compared with −0.3±2.1 (SD) ml/kg/min in the control group, as well as a significant change in the quality of life in older patients with heart failure.29

Traditional cardiac rehabilitation has focused on physical training and standardised programmes, but studies now indicate that individualised content and supervised exercise components can improve outcomes.30 In addition to exercise training, there is evidence to support interventions that include patient education, which in patients with coronary heart disease has shown to improve health-related quality of life and decrease healthcare costs31 and psychological support, which has been shown to improve psychological symptoms, such as depression and anxiety.32 Interventions designed to cover both physical and psychological problems may provide the best method for optimising functioning and enhancing the quality of life.33 We have not been able to identify randomised trials or observational studies in patients who have undergone RFA for AF that offer both psychoeducational intervention and physical training. Therefore, the CopenHeartRFA trial was undertaken with the aim of testing a rehabilitation programme consisting of physical exercise and a psychoeducational intervention versus treatment as usual for RFA-treated AF patients.

METHODS

Design

Major parts of the method section and trial design in this paper are similar to two other randomised clinical trials, CopenHeartVR and CopenHeartIE, and therefore
sections from this paper will be copied in these trial protocols (Sibilitz KL et al Effect of integrated cardiac rehabilitation vs treatment as usual for patients with isolated heart valve surgery: the randomised CopenHeart valvular trial protocol drafted October 2012 and Rasmussen et al8). The CopenHeartRFA trial is a multicentre, multidisciplinary randomised clinical superiority trial. Secondary qualitative data are also collected and the two methods are integrated by applying a mixed-method-embedded experimental design (figure 1).35 36 Quantitative methods are applied, with specified quantitative premeasures and post-measures, to evaluate the effect of the experimental intervention. Alongside quantitative measurements, qualitative data will be collected. The premise of mixed methods research is that the use of qualitative and quantitative approaches in combination provides a better understanding of the research problems than either approach alone, because different types of questions require different types of data and mixed methods research provides strengths that offset the weaknesses of both qualitative and quantitative research.34 The methods are integrated by applying a mixed-method-embedded experimental design and include qualitative data to develop the intervention and to examine the process of the intervention and the results of the trial (see figure 1).35 36 The rationale for this approach is that the quantitative findings provide a general understanding of the research problem through statistical results, whereas the qualitative findings refine and explain the results by exploring participants’ views in greater detail and will be presented by themes of patient thoughts or concerns about the intervention. Evaluation using qualitative research methods is increasingly promoted in evidence-based rehabilitation.37–40 Qualitative research alongside randomised controlled trials can contribute in several ways to the development and evaluation of complex healthcare interventions and may be particularly useful in evaluating interventions that involve social and behavioural processes that are difficult to explore or capture using quantitative methods alone.41 As patient participation is paramount for the efficacy of the rehabilitation,42 we find it highly valuable to include the patients’ perspective in the development and evaluation of the intervention. This paper presents the study protocol for the CopenHeartRFA randomised clinical trial. The complementary studies, including the qualitative part of the trial, are briefly described in a separate section.

The trial is described in accordance with the current SPIRIT guidelines (Standard Protocol Items: Recommendations for Interventional Trials).43 Results will be reported following the CONSORT (CONsolidated Standards Of Reporting Trials) guidelines for non-pharmacological interventions.44

**Trial hypotheses**

The primary hypothesis is that the rehabilitation programme increases physical capacity among AF patients treated with RFA after 4 months, measured by the VO2 peak, which is expected to be 20% more than in the control group receiving standard treatment alone. The estimate of 20% is based on findings from pilot studies including patients with permanent AF which found an increase of 15% in the VO2 peak. We therefore expect a VO2 peak in the intervention group of 18 and 15 ml/kg/min in the control group, corresponding to a difference of 20% (3 ml/kg/min).45

The secondary hypothesis is that the rehabilitation programme increases the quality of life and self-rated mental health among AF patients treated with RFA after 6 months by three points on the Medical Outcome Study SF-36 questionnaire mental component scale, compared with control participants receiving standard treatment.19

Exploratory hypotheses are that the experimental intervention decreases AF recurrence; improves self-rated health and sleep-quality; reduces early retirement from work, use of healthcare services and mortality, and is cost efficient.

**Trial participants**

Consecutive patients hospitalised for AF and treated with RFA at two heart centres in Denmark (Gentofte Hospital and Rigshospitalet, Copenhagen University Hospital) will be screened for inclusion and approached for trial participation (figure 2). Regardless of the RFA outcome, both patients with recurrent AF and patients in sinus rhythm after the ablation will be included in the trial. Patients 18 years of age or older, Danish speaking and providing verbal and written informed consent will be eligible for participation. Patients unable to understand trial instructions, pregnant or breastfeeding, with reduced ability to follow the planned programme due to other physical illness, who prior to RFA have been doing intense physical exercise or sports at a competitive level several times a week, or who do not wish to participate and patients already enrolled in clinical trials that prohibit participation in additional trials are excluded.

**Trial procedure, randomisation and follow-up**

Patients will be approached for participation during their hospitalisation for RFA. Information will be given by a nurse or physician from the research team, who will obtain written informed consent after the RFA procedure. A brief oral introduction is initially given together with written information describing the trial and
implications for the patient in detail. The patient is given ample time to read the information and, if necessary, involve a relative in the decision-making. The enrolling nurse or physician will return after the RFA or call the patient to answer any questions that the patient or their relative might have. The patient should subsequently be able to provide informed consent or reject participation. After the informed consent form is signed, baseline data will be collected including the baseline questionnaire package, demographic variables and clinical characteristics (table 1).

Then the Copenhagen Trial Unit (http://www.ctu.dk/) is contacted for central randomisation of the participant. Randomisation is conducted according to a computer-generated allocation sequence with a varying block size kept unknown to the investigators. Participants are randomised 1:1 to the experimental intervention group or the control group and stratified according to sex and type of AF (persistent or paroxysmal). Thus, neither the investigators nor the patients or relatives can influence the group to which the patients are allocated. For both groups, the follow-up assessment will take place at 1, 4, 6 and 12 months postdischarge, and a register-based follow-up assessment will be conducted at 24 months (table 1). In case of complications to the RFA after enrolment in the trial, the patients will be handled individually (eg, arrhythmia or inguinal haematoma).

The patients answer questionnaires independently of the researchers, and before randomisation. All questionnaires are distributed electronically; thus, data management is handled independently from the researchers who interpret the data. All data are stored electronically in a coded database, and in an independent spreadsheet, accessible only to the CopenHeart group.

Personal information about the potential and enrolled patients will be collected electronically and shared in a database accessible only to those within the project group responsible for patient recruitment, in order to protect confidentiality before, during and after the trial.

Owing to the nature of rehabilitation, the intervention group is not blinded to the patients or the investigators, but the outcome assessment of the primary outcome, the statistical analyses and drawing of conclusions will be conducted blinded to the allocated intervention group.

**Experimental intervention group**

Patients in the experimental intervention group will follow the integrated cardiac rehabilitation programme consisting of a psychoeducational component and an exercise training component alongside standard treatment (described below). The patients will be contacted at 1, 4, 6 and 12 months for outcome assessment including clinical data collection.

**Physical exercise training component**

The intervention has been developed and partly tested in a clinical rehabilitation trial, the COPE-ICD trial, which included patients with an implantable cardioverter defibrillator (ICD). Here, we observed a significant
The intervention has been modified for patients treated for AF with ablation as described below. The CopenHeart physical exercise intervention meets European24 and Danish guidelines61 for physical exercise in patients with heart disease, and complies with The National Danish Board of Health recommendations for physical exercise in daily living for heart patients.62

The physical exercise starts 1 month after ablation and comprises the following three elements:

- **Individually planned physical exercise by specially trained physiotherapists**
  - Integrating detailed information concerning the AF symptoms and RFA, comorbidity, hospitalisation, activities of daily living and level of physical activity prior to RFA, a specially trained physiotherapist conducts a patient telephone consultation up to 30 min. The consultation is based on initial testing of the patient including a cardiopulmonary exercise test, a 6-min walking test and a ‘sit to stand’ test, described in the outcome section. For all patients, a rehabilitation plan is prepared as an individual training diary, and all patients are instructed in the use of a heart rate monitor (Polar Watch provided by Rigshospitalet). The heart rate monitor and diary are essential to ensure CopenHeart training protocol compliance, and they are returned for data collection at the end of the exercise training intervention.

- **Intensive exercise training programme**
  - Physical exercise is initiated at Rigshospitalet 4 weeks after RFA to ensure optimal rest and healing. Using wireless electrodes integrated into T-shirts (Corus-Fit,
CardioCardio and Corus Exercise Assistant, CEA, V2.0.16, Finland), potential cardiac arrhythmias, ECG abnormalities such as ST depression, ST elevation, Q wave or T wave altering, AF and ventricular arrhythmias and training intensity level are monitored.

After 1–3 exercise training sessions at Righospitalet, the patient continues the programme at a local CopenHeart certified training facility supervised by physiotherapists or as supervised home-based training. Supervised home-based exercise training has shown similar results to hospital-based exercise training\(^3\) and has been confirmed in a Danish setting.\(^6\)

The physical exercise training continues for 12 weeks, comprising three weekly sessions of 60 min each, in total, 36 sessions. The training protocol consists of cardiovascular training and strength exercises to improve endurance and muscular strength.

An exercise session consists of 10 min warm-up, 20 min bicycling, 20 min strength and a 10 min stretching and cool-down period. Using the results from the cardiopulmonary exercise test performed prior to the initial training session, in combination with the Borg Scale measuring subjective exhaustion, the aerobic exercise is performed with gradually increasing intensity throughout the exercise intervention period, corresponding to 13–17 on the Borg Scale and 50–80% of the maximum heart rate. The anaerobic resistance training is initiated at 30–40% of one repetition maximum (RM) for the upper body and 40–50% of one RM for the lower body, with an increasing workload during the training sessions. To achieve cardiovascular adjustment and reduce the risk of malignant cardiac arrhythmias and ischaemia, the training session is initiated and terminated with a warm-up and a cool-down period to gradually increase and decrease the training intensity and heart rate. This cardiovascular adjustment has been proven to reduce the risk of ischaemia and arrhythmia in relation to exercise training.\(^6\)\(^4\)\(^6\) Training is predominantly performed in the upright position to reduce left ventricle preload (diastolic volume) and the risk of ischaemia and arrhythmias due to heart failure.\(^6\)

### Sustained moderate physical exercise daily

Participants are instructed to perform moderate physical exercise for at least 30 min a day during the intervention period, for example, bicycling, walking, gardening, jogging or recreational sports. Participants are encouraged to continue with moderate physical exercise throughout their lives.

### Psychoeducational component

The aim of the psychoeducational intervention is to provide emotional support and improve coping skills and illness appraisal in order to enable the patient to respond appropriately to physical and psychological symptoms. Education and information about the disease prepare the patient for expected symptoms and sensations. Dialogue and shared reflection facilitate strategies for coping with symptoms and experiences associated with the condition, for example, anxiety and fear. Cardiac care nurses with specific training will perform the psychoeducational intervention. Some of the most commonly reported concerns of patients treated for AF with RFA, such as recurrent AF, and concerns about being able to manage a working life are outlined in a guide which nurses use to address when and if relevant (see table 2). The information given will also be based on the national guidelines and standard treatment of patients treated for AF. The consultations focus on managing life after AF treated with RFA by establishing a joint approach to disease management and coping strategies, taking a holistic view. The psychoeducational intervention is inspired by R.R. Parse’s Human Becoming Practice Methodologies’ three dimensions.\(^6\)\(^6\) These are

| Table 2 | Guide to the psychoeducative consultation |
|---------|-----------------------------------------|
| Number visit | 1 | 2 | 3 | 4 |
| Ask the patient how he/she has been since the ablation. What has happened since the last time he/she was here? | X | X | X | X |
| Invite the patient to talk about his/her thoughts and questions | X | X | X | X |
| Ask about the time leading up to RFA and his/her AF history. Experiences before, under and after the hospitalisation and RFA | X |
| Talk about how it is to have had/have AF and been through RFA, how that affected the patient’s life. Is there something he/she avoids, or feels like he/she cannot do anymore? This is in relation to family relations, friends and free time/leisure activities | X |
| Make sure that the patient has started the physical training and talk about how it is going. Are training appointments booked? | X | X | X |
| Talk about if the patient has changed his/her feelings or thoughts of the body and its functions | X |
| Talk about recognition of symptoms, how the patient is feeling about the recurrence of AF and opinions about future AF treatment. Worries about the recurrence of AF, strategies of prevention | X | X | (X) | (X) |
| Information/recommendations in relation to the subjects/problems discussed | X | X | X | X |

Risom SS, Zwisler A-D, Rasmussen TB, et al. BMJ Open 2013;3:e002377. doi:10.1136/bmjopen-2012-002377
interpreted as: (1) to discuss and give meaning to the past, present and future, (2) to explore and discuss events and possibilities and (3) to move along with envisioned possibilities. According to this theory, there are three ways of changing health: creative imaging, that is to see, hear and feel what a situation might be like if lived in a different way, affirming personal patterns and value priorities and shedding light on paradoxes, that is, looking at the incongruence in a situation and changing the view held of something. The nurse is present in the process through discussions, silent immersion and reflection. The human becoming practice methodology was chosen to apply a holistic patient approach, focusing on the coping and transformation process of the individual person. Furthermore, the method is already extensively used in the outpatient heart clinics at the heart centre at Rigshospitalet, such as for patients with inherited heart diseases and adults with congenital heart disease, and is documented in the COPE-ICD trial.\(^6\)\(^8\) The consultations take place in a quiet setting at the outpatient clinic and will last for approximately 1 h. The nurse is able to facilitate contact with or seek advice from a physician if needed. The first consultation will be approximately 1 month after discharge, and then once every 4–6 weeks, with a total of four consultations. Consultations can be done by telephone, in accordance with the patient’s wishes. The primary investigator will attend the consultations regularly to ensure protocol compliance.

**Intervention deviations**

Both components of the intervention will be supervised regularly by the primary investigator to ensure protocol compliance. Modification of the allocated intervention due to surgery complications, rehospitalisation or emerging comorbidities (eg, recurrent AF and musculoskeletal problems) will be individually assessed, and the time of the primary outcome assessment at 4 months (described in section below) will be corrected in accordance with changes in the intervention.

**Control group: treatment as usual**

Patients in the control group will follow standard treatment for patients treated for AF with RFA including a 3–6-month follow-up with a physician and a 12-month follow-up with a nurse. Furthermore, patients will be contacted at 1, 4, 6 and 12 months for outcome assessment including clinical data collection.

**Outcomes and data collection**

Data will be collected to evaluate the effect and meaning of the intervention. The primary and secondary outcomes reflect the primary modifiable factors of the intervention. Since this is a complex intervention with two main components, an exercise component and a psychoeducational component, this is reflected in the primary and secondary outcomes. The intervention has been tested in ICD patients (unpublished data in the COPE-ICD trail, available on request) and reflects well in the chosen measures that have been found to be sensitive to changes based on the intervention. Since almost no evidence exists for rehabilitation programmes for patients treated for AF with RFA, data on a number of outcomes will be collected for exploratory analyses.

**Primary outcome**

Physical capacity is measured by peak VO\(_2\) according to a standardised protocol developed in accordance with the guidelines\(^6\)\(^8\)\(^9\)\(^1\)\(^4\)\(^1\)\(^2\) months after randomisation.

Physical capacity is measured by peak VO\(_2\) using cardiopulmonary exercise testing (Ergo-Spiro CS-200, Schiller, Switzerland). This is chosen as a primary outcome since this is standard in exercise-based rehabilitation trials. The test is performed according to current guidelines for ergospirometry testing, and by an ergometer bicycle, simultaneously monitoring heart rhythm, blood pressure, ECG and measuring gas exchange during workload and in the following recovery period. The average test duration is 10–15 min including the pretest and post-test phases without workload. Before each session, calibration is performed to address changes in room temperature, humidity and air oxygen content. A standardised ramp protocol is used with an initial workload of 25 or 50 watts, increasing gradually by 12.5 W/min until peak exhaustion. Peak exhaustion is evaluated by a respiratory exchange ratio $\geq T_1.10$ or by subjective exhaustion of the patient. In order to encourage the patients equally, independent of the tester, a standardised guide has been developed. During the test period, clinical manifestations, ECG abnormalities (ST depression, ST elevation, Q wave and T wave changes, supraventricular or ventricular arrhythmias), blood pressure response and several physiological variables are observed and documented. The test will be performed by either a cardiac care nurse or a physician. For safety reasons, preset criteria for initiation and/or termination of the test have been defined.

**Secondary outcome**

Self-rated mental health is measured by the SF-36 questionnaire,\(^2\)\(^0\)–\(^2\)\(^2\) mental component score, after 1, 4, 6 and 12 months (table 1).

**Exploratory outcomes**

**Long-term follow-up**

Register data regarding mortality, causes of death, hospitalisation/rehospitalisation, emergency room visits, outpatient visits, healthcare costs, visits to the general practitioner, medication use, employment status and payment of welfare benefits (sick leave payment and early retirement pension) will be collected at 24 months to assess the long-term effects of the intervention (table 1). Danish record keeping for the aforementioned data functions well, with only a small percentage of lost data.\(^2\)\(^3\) Consequently, the method is well suited as an outcome measure in small patient populations. Data will
be extracted from the Danish National Patient Register, the Danish National Health Service Register, the Danish National Prescription Registry, the Danish National Causes of Death Register and records of transfer payments and labour market affiliation.74–77

**Six minutes walking test**
The maximum walking distance (in metres) within 6 min is measured, using standardised instructions,46 while subjective exhaustion with regard to fatigue and dyspnoea using the Borg Scale78 is registered.

**Sit and stand test**
The maximum number of times a patient can sit and rise from a normal chair within 30 s is recorded. Subjective exhaustion is measured using the Borg exhaustion scale.78

**Biochemical screening**
Potassium, sodium, haemoglobin and creatine. One EDTA plasma heparin tube will be frozen (80°) for further analyses (pro-BNP, BNP, copeptin).

**Other exploratory outcomes**
AF recurrence, self-rated health and sleep-quality, retirement from work, use of healthcare services, mortality and cost efficiency (table 1).

**Sample size calculation for the primary outcome**
We are performing a randomised trial where the continuous variable VO₂ peak is the primary outcome. The control and intervention groups are independent, and the ratio of patients in the intervention group to the patients in the control group is 1:1. A previous trial of patients with permanent AF found that the VO₂ peak was normally distributed with an SD of 3.8 ml/kg/min.45 As the CopenHeartRFA trial has a more varied patient population that has been treated for AF with RFA, which means that the majority of the patients will have sinus rhythm and the rest will have AF, the patients are not directly comparable with the patients in the previous trial, and we assume an SD of 6 ml/kg/min to be more relevant. We consider a 0.5 SD to be the minimal relevant difference, equivalent to 3 ml/kg/min. Therefore, if the true difference between the intervention and control groups is 3 ml/kg/min and the SD is 6 ml/kg/min in the control group, 105 patients in the intervention group and 105 in the control group (a total of 210 patients) are needed to reject the null hypothesis, stating that the mean in the intervention and the control groups is the same, with a power of 95%. The type I error probability associated with this test of this null hypothesis is 5%.

**Power calculation for the secondary outcome**
The secondary outcome measure is the continuous variable mental component, SF-36. If the true difference between the intervention and control groups is 7 points, and the SD in the control group is 18 points,22 we will be able to reject the null hypothesis that the population means of the experimental and control groups are equal with a probability of (power) 0.80. The type I error probability associated with this test of this null hypothesis is 5%.

**Statistical analyses**
Data will be pseudoanonymised and analysed blinded by a trial-independent statistician using intention-to-treat analyses and a mixed model with repeated measures (MMRM) for continuous outcome measures.29 Using MMRM ensures that missing data values (in case of the primary and secondary outcomes) will not create bias as long as the values are missing at random. Two-sided tests are performed. The level of significance is set at 5%. With regard to multiplicity, gate keeping will be used to adjust the observed p values for primary and secondary outcomes.80 Both unadjusted and adjusted p values will be reported.

For the primary and secondary outcomes, sensitivity analysis will be conducted to assess the potential impact of values missing not at random. For each intervention group (A and B), some quantities (imputing quantities) are computed to be used to impute missing values in a group (A or B) as follows. A comparison between groups A and B, where missing values in group A are imputed using imputing quantities obtained from group B and vice versa, the comparison is called a worst case analysis. The imputing quantities for the primary outcome are the group mean at T1 (X1-bar), the group mean at T4 (X4-bar), the group mean at T6 (X6-bar), the mean difference between the value measured at T4 and that measured at T1 (δ1) and the mean difference between the value measured at T6 and that measured at T4 (δ2). Table 3 explains how the quantities are used to impute missing values in a group (either the same group or the other intervention group). If the SE of a parameter estimate calculated using imputed data is smaller than that of the corresponding parameter calculated using complete case data, it is replaced by the latter SE when the p value is calculated (table 3).

Long-term register-based outcomes will be analysed by two different models: non-negative count outcomes (eg, number of contacts with the hospital or number of visits to general practitioners) will be analysed by a Poisson model or a zero-inflated Poisson model if the number of zeros are large, and time-to-event data (eg, cause-specific mortality and leaving the labour market) will be analysed with survival methods (Kaplan-Meier estimator and Cox regression model). Especially for socioeconomic outcomes, competing risks due to mortality will be considered if a large proportion of patients die during follow-up.
Table 3  Statistical analysis

| Observed pattern in group B at 1, 4 and 6 months | Imputed value in group B at 1 month | Imputed value in group B at 4 month | Imputed value in group B at 6 months |
|--------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| mis*, mis, mis                                  | X1-bar†                           | X4-bar‡                           | X6-bar§                           |
| mis, mis, Y3‖                                   | Y3—(δ1”+δ2††)‡‡                  | Y3—δ2                             | Y3+δ2                             |
| mis, Y2, mis                                    | Y2—δ1                             | Y1+δ1                             | Y1+δ1+δ2                          |
| Y1, mis, mis                                    | Y2+δ2                             | (Y1+δ1+Y3—δ2)/2                   |                                    |
| Y1, Y2, mis                                     |                                    |                                    |                                    |
| mis, Y2, Y3                                     | Y2—δ—1                            |                                    |                                    |

Table to explain the use of imputing quantities derived from observed values in a group (group A) to impute missing values in a group (group B). mis, missing value, X1, value at month 1, X4, value at month 4, X6, value at month 6.
†*The value at 4 months is missing in group B.
††Mean of values observed in group A at time 1 month.
‡‡Mean of values observed in group A at time 4 months.
§Mean of values observed in group A at time 6 months.
¶Observed value in group B at time 6 months.
**The mean of difference between values observed at time 4 months and value observed at time 1 month in group A.
†††The mean of difference between value observed at time 6 months and value observed at time 4 months in group A.
††††If an imputed value is 0, it is set equal to 0.

Exploratory data will be analysed using appropriate statistical methods according to the type of data (see table 1). SPSS V.17.0 and SAS V.9.3 will be used.

INTERIM ANALYSIS AND DATA MONITORING SAFETY COMMITTEE

The Data Monitoring Safety Committee (DMSC) works independently of the funder and has no competing interests, and consists of two clinicians and a statistician. The committee is responsible for safeguarding the interests of trial participants, assessing the safety and efficacy of the interventions during the trial and for monitoring the overall conduct of the clinical trial. In line with the terms of the DMSC charter, one formal interim analysis meeting will be held to review data relating to treatment efficacy, participant safety and quality of trial conduct. The three members of the DMSC will meet when the 12-week follow-up data of about 50% of the trial participants have been obtained. Any serious adverse events will be registered as part of the data collection and the overall number of adverse events will be reported at the meeting.

Complementary studies

Survey-based study

The postdischarge status of the patients treated with RFA will be explored through a national survey. The standardised questionnaires SF-36,49 Hospital Anxiety and Depression Scale,50 EuroQoL-EQ-5D,51 52 Heart Related Quality of Life,53 International Physical Activity Questionnaire,54 55 and a questionnaire developed by the Danish Heart Foundation on the extent and quality of rehabilitation offered will be sent to patients having undergone treatment for RFA, 6–12 months post-discharge. The instruments are all validated and have good reliability and responsiveness.50 54 56 57 81 82 The data will provide knowledge on patients’ self-rated health, quality of life, anxiety and depression, economic situation and the extent and quality of the rehabilitation currently received. Patients were identified through the National Patient Register74 and questionnaires were sent out to 608 patients. We anticipate that 25% will decline participation, leaving an estimated 456 questionnaire respondents. Data will be anonymised and analysed by relevant descriptive statistical methods.

Qualitative postintervention study

After the intervention, 10% of the participants from the intervention group will be strategically chosen for an interview in order to explore the experiences and processes behind the potential effects of the intervention. The qualitative study will explore patient experiences of participating in the CopenHeart RFA programme and investigate which components were meaningful.

To achieve maximum variation, qualified interviewees are chosen on the basis of sex, AF type and current heart rhythm.83 The analysis will be inspired by Ricoeur’s theory of interpretation consisting of three levels: naive reading, structured analysis and critical interpretation and discussion.84 The results will be presented in themes based on patient experience and evaluation of the intervention. As an example, we will look for explanations for the results in physical capacity and mental health as described by the patients. We are using a mixed-method approach to explore all aspects of the intervention, but the qualitative findings are seen as a complementary study to the primary randomised clinical trial.

Economic evaluation

An economic evaluation will be conducted alongside the trial to assess the cost-utility of cardiac rehabilitation compared with treatment as usual in the study population. The economic evaluation will compare the costs to
quality-adjusted life years (QALY) and take a societal perspective, as recommended nationally. QALYs and costs will be assessed at the end of the intervention, 6 months from randomisation, and later after 24 months from randomisation using the register-based follow-up.

QALYs will be estimated using the self-completed EQ-5D instrument, which is a standardised instrument assessing five dimensions of self-reported health status (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The estimated calculations will be valued using Danish preference weights. Information on costs will only include costs that are expected to differ between the intervention group and usual care group. Costs included in the evaluation are health costs associated with the rehabilitation programme, other healthcare costs (healthcare utilisation besides rehabilitation), patient costs and costs of productivity losses. Information on costs will be collected by a mixture of activity-based costing, surveys, patient diary and by the use of public records. Results from the analysis will be reported as an incremental cost-effectiveness analysis (ICER). Sensitivity analysis will be conducted to express uncertainty in the estimates. The reporting of the ICER is presented using Bayesian methods, including bootstrapping and as cost-effectiveness acceptability curves.

**Ethics**

The inclusion started in December 2011 and is approved by the Regional Ethics Committee (number H-1-2011-135) and the Danish Data Protection Agency (no. 2007-58-0015). All eligible patients will be informed about the trial verbally and in writing, and they are included after informed consent has been obtained. All data will be handled confidentially and patients ensured anonymity. The trial complies with the latest Declaration of Helsinki and is registered at ClinicalTrials.gov (NCT01523145). An independent international safety committee monitors the trial. All serious and adverse events will be registered and reported in accordance with the safety charter.

Not providing rehabilitation to the control group can be ethically justified as current national and international guidelines give no specific recommendations on cardiac rehabilitation for patients treated for AF with RFA. The scope and quality of rehabilitation offered to this population is unknown, but suspicions are that generally no rehabilitation is offered in Denmark. The only way patients can get supervised exercise training is if they voluntarily enrol in a programme, for example, through non-profit organisations. The survey-based complementary study, described previously in this paper, will hopefully provide more insight into this. In screening patients for participation, the enrolling nurse or physician will exclude those with a compelling rehabilitation need. Furthermore, patients are informed of the study design before giving their consent, and are free to decline participation.

**DISCUSSION**

Owing to the difference in the three patient groups that are included in the overall CopenHeart trial, patients treated for infective endocarditis, heart valve surgery and for AF patients treated with RFA, the intervention and outcome measures differ slightly, most importantly in the case of the psychoeducational intervention, which is longer for patients treated for infective endocarditis and heart valve surgery, because of the complexity of the diseases and the longer hospitalisation. Similarly, biochemical markers are chosen differently to address the various comorbidities of the three diseases and some disease specific questionnaires are chosen to capture the specific disease-relevant issues.

To our knowledge, no previous randomised clinical trials or observational studies have been conducted that focus on integrated cardiac rehabilitation for AF patients treated with RFA, and therefore it is not known what effect, if any, rehabilitation has on these patients. However, in the light of evidence from other groups of patients with heart disease, a positive effect can be expected.

This trial is different from previous trials because we apply a comprehensive rehabilitation intervention which consists of both a physical training component and a psychoeducational component. This combination is hypothesised to strengthen the patient both physically and mentally even if the patient has AF. Also, we use a mixed-method approach, which has its strengths in using both qualitative and quantitative research designs.

The major strengths of this randomised clinical trial are that it includes consecutive patients with a reasonable number of inclusion and exclusion criteria securing external validity for the results. The trial employs central, stratified randomisation which secures against selection bias. The primary outcome is assessed blinded to intervention and so are all statistical analyses, which should reduce detection and interpretation bias. The long-term outcomes are based on data taken from public registry data, which are also likely to not include biased reporting of outcomes.

The secondary outcomes of self-rated mental health are subjective by nature and are likely to be biased. The patients answer questionnaires independently of the researchers. Data management is handled independently of the researchers who interpret data. All questionnaires are distributed electronically. All data entry is stored electronically in a coded database, and in an independent spreadsheet, accessible only to the CopenHeart Group.

The trial limitations include the fact that it is known from previous rehabilitation trials that patients in the control group have a tendency to do physical training due to the focus on the subject in the recruitment process. We will be aware of that when we recruit and not focus on giving extensive information about the exercise programme, or encourage patients to do physical training before knowing which group they are
randomised to. Any difference between patients completing the intervention and those not completing (dropouts) will be carefully discussed when evaluating the intervention, results and the suitability for implementation. The trial is designed with multiple statistical comparisons, so results will be interpreted with caution. Further limitations of the trial and methods used are similar to those of other trials including physical exercise and physical testing, namely time-of-day and day-to-day variation using exercise testing. To ensure standard testing of all physical exercise tests in the trial, standardised instructions for patients have been developed as described in the methods section. Conversely, the trial population will be representative of the true RFA population, meaning that some patients will have AF and some sinus rhythm while exercising and testing, and this will facilitate implementation of The CopenHeart RFA trial rehabilitation programme in daily clinical practice. We are aware that patients treated with RFA are a highly select group of patients with paroxysmal or persistent AF, and they are more likely to participate properly and complete a rehabilitation programme, compared with patients with, for example, permanent AF, since patients with permanent AF are often older and suffer from comorbidity. Therefore we do not expect to generalise the results to all AF patients.

The challenge with the set-up is that patients come from considerable distances, and therefore some will decline participation. Also, owing to the nature of rehabilitation trials, the patients have to meet at the hospital frequently, especially when randomised to the experimental intervention group.

The trial will, to our knowledge, be the largest trial conducted that deals with rehabilitation AF ablation recipients. If a positive effect of integrated rehabilitation is found, it may have an impact on the rehabilitation offered to patients treated for AF with RFA at the international level. The trial is expected to identify an intervention which can improve the health and quality of life of patients, and subsequently reduce healthcare utilisation and costs, as well as mortality.

**Contributors** SKB and ADZ designed the trial in collaboration with SSR, JLH, MP, LCT, PW and CG. SSR drafted the manuscript in collaboration with SKB, ADZ, TBR, KLS, JHS, CG, LCT, SD, JLH and SD. All revised the manuscript critically. All authors have given their final approval of the version to be published.

**Funding** The trial is partly funded by The Danish Council for Strategic Research (number: 10-092790), The Lundbeck Foundation (journal number: PP 62/2011 and FP 74/2012) and The Heart Centre at Rigshospitalet. The funders have no influence on the trial design, the execution of the trial or the interpretation of the data.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** The regional research ethics committee: no: H-1-2011-135.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**

1. Stewart S, Hart CL. Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. *Heart* 2001;86:516–21.

2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AmTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;285:2370–5.

3. Ruigomez A, Johansson S, Wallander MA, et al. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. *BMC Cardiovasc Disord* 2005;5:20.

4. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Europace* 2010;12:1360–420.

5. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation (Review) 2009;The Cochrane Libraly(1).

6. Kirchhof P, Aurichio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. *Europace* 2007;9:1006–23.

7. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002;113:359–64.

8. Camm J. Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits. *Int J Cardiol* 2011;155:362–71.

9. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J* 2006;27:949–53.

10. Naccarelli GV, Vacker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. *Am J Cardiol* 2009;104:1534–9.

11. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 2004;110:1042–9.

12. Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: the cost of illness of atrial fibrillation and flutter in the United States. *Am Heart J* 2011;161:418–24.

13. Wolowacz SE, Samuel M, Brennan VK, et al. Non-pharmacologic management of atrial fibrillation (Review) 2009;The Cochrane Libraly(1).

14. Brenyo AJ, Aktas MK. Antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. *Circ Arrhythm Electrophysiol* 2009;2:349–61.

15. Atwood JE, Myers JN, Tang XC, et al. Exercise capacity in atrial fibrillation: a study of the Sotolotol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). *Am Heart J* 2007;153:566–72.

16. Hansson A, Madsen-Hardt B, Olsson SB. Arthritis-inducing factors and symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with 100 patients seeking hospital assistance. *BMC Cardiovasc Disord* 2004;4:13.

17. Hegbom F, Sire S, Heldal M, et al. Short-term exercise training in patients with chronic atrial fibrillation: effects on exercise capacity,
tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247–63.
73. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263–8.
74. Lyne E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39(7 Suppl):30–3.
75. Andersen JS, Olivarius Nd F, Krasnik A. The Danish National Health Service Register. Scand J Public Health 2011;39(7 Suppl):34–7.
76. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39(7 Suppl):38–41.
77. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39(7 Suppl):26–9.
78. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81.
79. De Souza CM, Legedza AT, Sankoh AJ. An overview of practical approaches for handling missing data in clinical trials. J Biopharm Stat 2009;19:1055–73.
80. Dmitrienko A, Wiens BL, Tamhane AC, et al. Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Stat Med 2007;26:2465–78.
81. McHorney CA, Ware JE, Rogers W, et al. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts: results from the Medical Outcomes Study. Med Care 1992;30(Suppl):253–65.
82. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart 2006;92:62–7.
83. Polt DF, Beck CT. Essentials of nursing research: methods, appraisal, and utilization. 6 edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2006.
84. Ricoeur P. Interpretation theory: discourse and the surplus of meaning. 5th print edn. Fort Worth, TX: Texas Christian University Press, 1976.
85. EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199–208.
86. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72.
87. Wittrup-Jensen KU, Lauridsen J, Gudex C, et al. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health 2009;37:459–66.
88. Fox-Rushby JA, Caimis J. Economic evaluation. Maidenhead: Open University Press, 2005.
89. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779–87.
90. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116:682–92.
91. Rees K, Taylor RS, Singh S, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2004;(3):CD003331.
92. Wood L, Egger M, Glaud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601–5.
93. Gluud L. Bias in clinical intervention research. Am J Epidemiol 2006;163:493–501.
94. Savovic J, Jones H, Altman D, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012;16:1–82.
95. Rowland T, Unnithan V, Barker P, et al. Time-of-day effect on cardiac responses to progressive exercise. Chronobiol Int 2011;28:811–16.